Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.

Resistance to trastuzumab, a rationally designed HER-2-targeting antibody, remains a major hurdle in the management of HER-2-positive breast cancer. Preclinical studies suggest the mechanisms of trastuzumab resistance are numerous. Unfortunately, the majority of these studies are based around HER-2-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David Lesniak, Siham Sabri, Yaoxian Xu, Kathryn Graham, Pravin Bhatnagar, Mavanur Suresh, Bassam Abdulkarim
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ea5bd0be082147b9a2a176976bfc2bc9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea5bd0be082147b9a2a176976bfc2bc9
record_format	dspace
spelling	oai:doaj.org-article:ea5bd0be082147b9a2a176976bfc2bc92021-11-18T08:58:15ZSpontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.1932-620310.1371/journal.pone.0071987https://doaj.org/article/ea5bd0be082147b9a2a176976bfc2bc92013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23991019/?tool=EBIhttps://doaj.org/toc/1932-6203Resistance to trastuzumab, a rationally designed HER-2-targeting antibody, remains a major hurdle in the management of HER-2-positive breast cancer. Preclinical studies suggest the mechanisms of trastuzumab resistance are numerous. Unfortunately, the majority of these studies are based around HER-2-positive (HER-2+) luminal cell lines. The role of epithelial to mesenchymal transition (EMT), a genetic program that confers a basal phenotype, may represent a novel mechanism of escape for HER-2+ luminal cells from trastuzumab treatment. Here we investigated this possibility using a model of clonal selection in HER-2+ luminal breast cancer cells. Following a random isolation and expansion of "colony clusters" from SKBR-3 cell lines, several colony clusters underwent a spontaneous EMT in-vitro. In addition to expression of conventional EMT markers, all mesenchymal colony clusters displayed a predominant CD44+/CD24- phenotype with decreased HER-2 expression and elevated levels of a β1-integrin isoform with a high degree of N-glycosylation. Treatment with a β1-integrin function-blocking antibody, AIIB2, preferentially decreased the N-glycosylated form of β1-integrin, impaired mammosphere formation and restored epithelial phenotype in mesenchymal colony clusters. Using this model we provide the first clear evidence that resistance to trastuzumab (and lapatinib) can occur spontaneously as HER-2+ cells shift from a luminal to a basal/mesenchymal phenotype following EMT. While the major determinant of trastuzumab resistance in mesenchymal colony clusters is likely the down regulation of the HER-2 protein, our evidence suggests that multiple factors may contribute, including expression of N-glycosylated β1-integrin.David LesniakSiham SabriYaoxian XuKathryn GrahamPravin BhatnagarMavanur SureshBassam AbdulkarimPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 8, p e71987 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q David Lesniak Siham Sabri Yaoxian Xu Kathryn Graham Pravin Bhatnagar Mavanur Suresh Bassam Abdulkarim Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
description	Resistance to trastuzumab, a rationally designed HER-2-targeting antibody, remains a major hurdle in the management of HER-2-positive breast cancer. Preclinical studies suggest the mechanisms of trastuzumab resistance are numerous. Unfortunately, the majority of these studies are based around HER-2-positive (HER-2+) luminal cell lines. The role of epithelial to mesenchymal transition (EMT), a genetic program that confers a basal phenotype, may represent a novel mechanism of escape for HER-2+ luminal cells from trastuzumab treatment. Here we investigated this possibility using a model of clonal selection in HER-2+ luminal breast cancer cells. Following a random isolation and expansion of "colony clusters" from SKBR-3 cell lines, several colony clusters underwent a spontaneous EMT in-vitro. In addition to expression of conventional EMT markers, all mesenchymal colony clusters displayed a predominant CD44+/CD24- phenotype with decreased HER-2 expression and elevated levels of a β1-integrin isoform with a high degree of N-glycosylation. Treatment with a β1-integrin function-blocking antibody, AIIB2, preferentially decreased the N-glycosylated form of β1-integrin, impaired mammosphere formation and restored epithelial phenotype in mesenchymal colony clusters. Using this model we provide the first clear evidence that resistance to trastuzumab (and lapatinib) can occur spontaneously as HER-2+ cells shift from a luminal to a basal/mesenchymal phenotype following EMT. While the major determinant of trastuzumab resistance in mesenchymal colony clusters is likely the down regulation of the HER-2 protein, our evidence suggests that multiple factors may contribute, including expression of N-glycosylated β1-integrin.
format	article
author	David Lesniak Siham Sabri Yaoxian Xu Kathryn Graham Pravin Bhatnagar Mavanur Suresh Bassam Abdulkarim
author_facet	David Lesniak Siham Sabri Yaoxian Xu Kathryn Graham Pravin Bhatnagar Mavanur Suresh Bassam Abdulkarim
author_sort	David Lesniak
title	Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
title_short	Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
title_full	Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
title_fullStr	Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
title_full_unstemmed	Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
title_sort	spontaneous epithelial-mesenchymal transition and resistance to her-2-targeted therapies in her-2-positive luminal breast cancer.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/ea5bd0be082147b9a2a176976bfc2bc9
work_keys_str_mv	AT davidlesniak spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer AT sihamsabri spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer AT yaoxianxu spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer AT kathryngraham spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer AT pravinbhatnagar spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer AT mavanursuresh spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer AT bassamabdulkarim spontaneousepithelialmesenchymaltransitionandresistancetoher2targetedtherapiesinher2positiveluminalbreastcancer
_version_	1718421117177167872

Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.

Ejemplares similares